Investors & Media Press Releases Investor Relations Overview Corporate Governance Press Releases & Statements Events & Presentations SEC Filings Annuals and Proxies Investor FAQs Financials & Filings Stock Information Analyst Coverage Email Alerts Subscription Notice of Pendency of Settlement of Action Press Releases Items Per Page 102550 Year None2023202220212020201920182017 Date Title View Toggle Summary May 3, 2023 Sage Therapeutics to Present at Upcoming May Investor Conferences Sage Therapeutics to Present at Upcoming May Investor Conferences Toggle Summary May 2, 2023 Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Toggle Summary April 18, 2023 Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023 Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023 Toggle Summary March 22, 2023 Sage Therapeutics to Present at the Stifel 2023 CNS Days Sage Therapeutics to Present at the Stifel 2023 CNS Days Toggle Summary March 16, 2023 Sage Therapeutics Appoints Jessica Federer to Board of Directors Sage Therapeutics Appoints Jessica Federer to Board of Directors Toggle Summary March 8, 2023 Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone Toggle Summary February 28, 2023 Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference Toggle Summary February 22, 2023 Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease Toggle Summary February 16, 2023 Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress Toggle Summary February 6, 2023 Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Next page Next Last page Last Displaying 11 - 20 of 23
Press Releases Items Per Page 102550 Year None2023202220212020201920182017 Date Title View Toggle Summary May 3, 2023 Sage Therapeutics to Present at Upcoming May Investor Conferences Sage Therapeutics to Present at Upcoming May Investor Conferences Toggle Summary May 2, 2023 Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Toggle Summary April 18, 2023 Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023 Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023 Toggle Summary March 22, 2023 Sage Therapeutics to Present at the Stifel 2023 CNS Days Sage Therapeutics to Present at the Stifel 2023 CNS Days Toggle Summary March 16, 2023 Sage Therapeutics Appoints Jessica Federer to Board of Directors Sage Therapeutics Appoints Jessica Federer to Board of Directors Toggle Summary March 8, 2023 Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone Toggle Summary February 28, 2023 Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference Toggle Summary February 22, 2023 Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease Toggle Summary February 16, 2023 Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress Toggle Summary February 6, 2023 Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Next page Next Last page Last Displaying 11 - 20 of 23
